CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

Valuation also favors CVS. While UNH trades at a forward P/E of 12.98X, CVS trades at a more modest 10.31. This valuation gap ...

CVS Health CVS has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Experts warn more research is needed on long-term safety THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more ...

Prescriptions of Wegovy to teens rose 50% in 2024, according to Truveta, a health data company. The drug was prescribed to 14.8 of every 100,000 adolescents, up from 9.9 in 2023. Wegovy was ...